prostatic adenocarcinoma
Item
prostatic adenocarcinoma without evidence of regional or distant metastases, clinical stage t1c-t2c with gleason score > 7 on initial biopsy and psa > 10 ng/dl or clinical stage t3.
boolean
C0007112 (UMLS CUI [1])
C1300072 (UMLS CUI [2])
ct, bone scan
Item
negative bone scan and ct abd/pelvis.
boolean
C0040405 (UMLS CUI [1])
C0203668 (UMLS CUI [2])
life expectancy
Item
life expectancy of at least 10 years.
boolean
C0023671 (UMLS CUI [1])
radical prostatectomy
Item
surgical candidate for radical prostatectomy and ecog performance status of < 2.
boolean
C0194810 (UMLS CUI [1])
C1520224 (UMLS CUI [2])
malignancies
Item
patients must have no other concurrent malignancies (or within the past 5 years, with the exception of non-melanoma skin cancer or treated superficial transitional cell carcinoma of the bladder).
boolean
C0006826 (UMLS CUI [1])
organ function
Item
peripheral granulocyte count > 1,500/mm3, platelet count of > 100,000/mm3 and hb> 10.0 gm/dl, adequate hepatic function with a bilirubin < 1.5 mg % and sgpt < 2.5x the upper limits of normal, and adequate renal function defined as serum creatinine < 1.5 mg% or creatinine clearance > 40 ml/min.
boolean
C0857490 (UMLS CUI [1])
C0032181 (UMLS CUI [2])
C0518015 (UMLS CUI [3])
C1278039 (UMLS CUI [4])
C0201836 (UMLS CUI [5])
C0201976 (UMLS CUI [6])
C0373595 (UMLS CUI [7])
hypothyroidism
Item
patients with biochemical hypothyroidism will have their thyroid hormone replaced concurrent with starting the study. patients with clinical hypothyroidism should have their thyroid replaced prior to starting this study.
boolean
C0020676 (UMLS CUI [1])
informed consent
Item
informed consent indicating that patients are aware of the investigational nature of the study, in keeping with the policies of the institution. the only approved consent form is appended to this protocol.
boolean
C0021430 (UMLS CUI [1])
compliance
Item
patients must be willing and able to travel to ut-mdacc for re-evaluation as necessary per protocol.
boolean
C1321605 (UMLS CUI [1])
thalidomide, contraception
Item
patients should be counseled about the possibility that thalidomide may be present in the semen and must use a latex condom every time they have sexual intercourse with a woman during therapy and for 4 weeks after discontinuing thalidomide, even if they had a successful vasectomy.
boolean
C0039736 (UMLS CUI [1])
C0700589 (UMLS CUI [2,1])
C0009653 (UMLS CUI [2,2])
therapy
Item
patients who have received any prior hormonal-, immuno-, radiation or chemo-therapy for prostate carcinoma are excluded from the trial. prior herbal and/or homeopathic medication is allowed if discontinued at least 2 weeks prior to study entry. pc-spes is considered hormonal therapy.
boolean
C0087111 (UMLS CUI [1])
hemorrhage
Item
patients with history of substantial non-iatrogenic bleeding diathesis and patients with macroscopic hematuria or active gi bleeding are not eligible.
boolean
C0019080 (UMLS CUI [1])
comorbidity
Item
patients with uncontrolled cardiac, respiratory, hepatic, renal, neurologic or psychiatric disorder are excluded from the trial.
boolean
C0009488 (UMLS CUI [1])
peripheral neuropathy, anticonvulsants
Item
patients with nci grade 2 or greater peripheral neuropathy of any cause (clinically detectable), or receiving anti-convulsive medications are not eligible for this trial.
boolean
C0031117 (UMLS CUI [1])
C0003286 (UMLS CUI [2])
medication
Item
patients who are receiving sedative/hypnotic agents which cannot be discontinued (if necessary) are not eligible for this study.
boolean
C0013227 (UMLS CUI [1])
hiv
Item
patients positive for hiv are excluded from this trial.
boolean
C0019682 (UMLS CUI [1])